Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$107.89 -1.7%	$120.70	$64.11 ▼ $139.13	$5.26B	0.88	658,820 shs	754,308 shs
BNTX BioNTech	$92.01 -1.4%	$109.42	$76.53 ▼ $131.49	$22.08B	0.3	835,302 shs	937,143 shs
SMMT Summit Therapeutics	$18.91 -7.6%	$20.28	$2.10 ▼ $33.89	$13.95B	-1.04	3.43 million shs	3.45 million shs
TEVA Teva Pharmaceutical Industries	$14.85 -2.9%	$16.67	$12.51 ▼ $22.80	$16.83B	0.82	9.66 million shs	8.17 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.69%	-11.40%	-14.08%	+24.80%	+46.79%
BNTX BioNTech	-1.40%	-3.55%	-16.09%	-20.54%	+1.35%
SMMT Summit Therapeutics	-7.58%	-8.20%	-0.94%	+3.67%	+378.73%
TEVA Teva Pharmaceutical Industries	-3.04%	-4.37%	-5.01%	-30.11%	+5.06%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6661 of 5 stars	4.5	3.0	0.0	4.5	1.8	4.2	0.6
BNTX BioNTech	2.734 of 5 stars	4.4	2.0	0.0	0.0	2.4	0.8	0.6
SMMT Summit Therapeutics	2.7277 of 5 stars	4.5	2.0	0.0	0.0	2.6	1.7	0.0
TEVA Teva Pharmaceutical Industries	2.3063 of 5 stars	3.4	3.0	0.8	0.0	2.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.00	Buy	$167.64	55.38% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	55.89% Upside
SMMT Summit Therapeutics	3.00	Buy	$35.44	87.44% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	57.82% Upside

Current Analyst Ratings Breakdown

Latest AXSM, BNTX, TEVA, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
4/1/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$153.00 ➝ $153.00
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/27/2025	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$212.00 ➝ $216.00
3/26/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$23.00 ➝ $35.00
3/21/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.64	N/A	N/A	$1.18 per share	91.43
BNTX BioNTech	$2.75B	8.03	$3.96 per share	23.25	$92.17 per share	1.00
SMMT Summit Therapeutics	$700K	19,927.90	N/A	N/A	$0.11 per share	171.91
TEVA Teva Pharmaceutical Industries	$16.54B	1.02	$2.94 per share	5.05	$4.75 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.99	N/A	38.26	N/A	-74.47%	-223.51%	-39.88%	5/5/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.31	N/A	N/A	N/A	N/A	-85.42%	-52.66%	4/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.64	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest AXSM, BNTX, TEVA, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	SMMT Summit Therapeutics	-$0.0715	N/A	N/A	N/A	N/A	N/A
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/18/2025	Q4 2024	AXSM Axsome Therapeutics	-$0.97	-$0.96	+$0.01	-$1.54	$117.83 million	$118.77 million
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.66%	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.81%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.22	2.11	2.04
BNTX BioNTech	0.01	7.33	7.21
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BNTX BioNTech	15.52%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
BNTX BioNTech	19.20%
SMMT Summit Therapeutics	88.30%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	48.77 million	37.84 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
SMMT Summit Therapeutics	110	737.68 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

AXSM, BNTX, TEVA, and SMMT Headlines

Recent News About These Companies

B. Metzler seel. Sohn & Co. AG Buys 50,995 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 4 at 4:49 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

April 4 at 2:09 AM | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Up 25.1% in March

April 3 at 6:05 PM | marketbeat.com

Pictet Asset Management Holding SA Buys 52,938 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 3 at 4:18 AM | marketbeat.com

Pharmaceuticals excluded from reciprocal tariffs announced by Trump

April 2 at 7:39 PM | msn.com

Schroder Investment Management Group Increases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:49 AM | marketbeat.com

DnB Asset Management AS Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:39 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by UniSuper Management Pty Ltd

April 2 at 4:15 AM | marketbeat.com

Korea Investment CORP Purchases 159,899 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:06 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Shares Up 2.5% - Still a Buy?

April 1 at 3:31 PM | marketbeat.com

Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

April 1 at 1:24 PM | msn.com

Latest Teva data in schizophrenia for long-acting injectable of olanzapine

April 1 at 8:22 AM | thepharmaletter.com

Arrowstreet Capital Limited Partnership Has $154.07 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 1 at 5:09 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Buys 70,978 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 1 at 4:05 AM | marketbeat.com

Teva announces presentation of survey study on TEV-‘749

April 1 at 3:22 AM | markets.businessinsider.com

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

March 31, 2025 | globenewswire.com

Dorsey Wright & Associates Sells 37,975 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 31, 2025 | marketbeat.com

Sei Investments Co. Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 31, 2025 | marketbeat.com

Okabena Investment Services Inc. Trims Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 30, 2025 | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Has $12.75 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 30, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Analysts

March 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM, BNTX, TEVA, and SMMT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$107.89 -1.86 (-1.69%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$105.54 -2.36 (-2.18%)

As of 07:42 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

BioNTech NASDAQ:BNTX

$92.01 -1.31 (-1.40%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$88.50 -3.51 (-3.81%)

As of 07:50 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Summit Therapeutics NASDAQ:SMMT

$18.91 -1.55 (-7.58%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$17.85 -1.06 (-5.60%)

As of 07:46 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$14.84 -0.45 (-2.91%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$14.22 -0.63 (-4.24%)

As of 07:50 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time